Results 71 to 80 of about 13,138 (168)

Autophagy in MASLD: A Metabolic and Precision Medicine Perspective

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide and a major contributor to cirrhosis and hepatocellular carcinoma (HCC). While metabolic triggers such as obesity and insulin resistance are key drivers of MASLD, growing evidence has identified defects in intracellular quality
Alessandra Cazzaniga, Silvia Frigo, Alessandro Cherubini, Eniada Rrapaj, Luca Valenti   +4 more
wiley   +1 more source

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension

PPAR Research, 2011
Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-
Dexter L. Lee, Justin L. Wilson, Rong Duan, Tamaro Hudson, Ahmed El-Marakby   +4 more
doaj   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes

Cardiovascular Diabetology
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease.
Jiwon Park, Hangyul Song, Shinje Moon, Yumin Kim, Sungsoo Cho, Kyungdo Han, Cheol-Young Park, Sung Woo Cho, Chang-Myung Oh   +8 more
doaj   +1 more source

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia

Cost Effectiveness and Resource Allocation
Background This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications
Hansoo Kim, Juntao Lyu, Vikrama Raja, Kyoo Kim   +3 more
doaj   +1 more source

Fenofibrate modified-release pellets with lag phase and high oral bioavailability

Drug Design, Development and Therapy, 2018
Fang Li,1,* Xin Zheng,2,* YongChu Bao,3 Ting Chen,3 Jia Zeng,1 XiaoLi Xu,4 Chao Yan,5 LingLin Feng1 1NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, and Shanghai Engineer and ...
Li F, Zheng X, Bao YC, Chen T, Zeng J, Xu XL, Yan C, Feng LL   +7 more
doaj  

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins. [PDF]

Front Cardiovasc Med
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Farnier M, Pushpa K, Tokgözoglu L, Zambon A, Berrou JP, Hermans MP.   +10 more
europepmc   +1 more source

Fenofibrate attenuates hyperhomocysteinemia-potentiated thrombosis by restoring platelet fatty acid β-oxidation. [PDF]

Redox Biol
Han L, Du X, Yan Y, Zhang L, Feng J, Wang X, Zhang X.   +6 more
europepmc   +1 more source

Fenofibrate mitigates microglial activation by reprogramming lipid metabolism and inhibiting ferroptosis. [PDF]

Mol Cell Biochem
Taskesen A, Hacioglu C, Tuncer S, Kilic G, Tuncer C.   +4 more
europepmc   +1 more source

A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. [PDF]

Am J Case Rep
Wang J, Lu Z, Zhou C.
europepmc   +1 more source